Short-Term Debt to Equity Ratio: Voyager Therapeutics (VYGR)
The market valuation dynamics for Voyager Therapeutics (VYGR) demonstrate a figure of 0.04, while the business faces international patenting risks and raw material supply chain complexities. Steady interest in cutting-edge treatments makes the company a resilient defensive asset with little dependence on general economic trends. However, success relies on partnerships with industry behemoths, which creates the risk of project loss.
Analytical breakdowns for voyagertherapeutics.com (VYGR)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Voyager Therapeutics|VYGR - Long-Term Debt to Equity|Short-Term Debt to Equity Voyager Therapeutics, Inc.|VYGR - Company Cumulative Debt|Debt to Book Value Voyager Therapeutics Inc|VYGR - Long-Term Debt|Company Short-Term Debts Voyager Therapeutics|Quick Ratio voyagertherapeutics.com
- company profitability and valuation multiples indicators:
Analysis of all company metrics:Voyager Pharma VYGR
This metric measures the share of short-term liabilities within the equity structure, determining the company's liquidity and financial stability over a one-year horizon. Investors analyze the ratio of short-term debt to equity to assess refinancing risks during periods of rate volatility. A decrease in this metric confirms solvency, which is critical for Voyager Therapeutics (VYGR) as it scales AI-driven capsid screening. The automation of laboratory tests requires stable funding without excessive pressure from short-term loans.
Competitors of Voyager Therapeutics (VYGR)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|Short-Term Debt to Equity DNLI|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN - Current Liabilities to Capital|Amylyx - Short-Term Debt to Equity Ratio|Trevi Corp (TRVI) - Current Liabilities to Capital|Praxis Precision Medicines - Short-Term Debt to Capital|AVXL - Short-Term Debt to Capital|CBLL: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Prothena Biosciences PRTA|ALEC (Alector Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Annexon Biosciences Inc. ANNX|Short-Term Debt to Equity Omeros Corporation (OMER)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NMRA|SCLX: Short-Term Debt to Equity Ratio|Tevogen Bio Inc. - Short-Term Loans to Capital Ratio|ACOG: Short-Term Debt to Capital|cogrx.com - Ratio of Short-Term Indebtedness to Capital|IKT (Inhibikase Therapeutics, Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Cassava Sciences Inc SAVA|Short-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|COYA (coyatherapeutics.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VTGN (Vistagen)|Short-Term Debt to Capital Ovid Therapeutics Inc OVID|ABOS - Short-Term Debt to Equity|Current Liabilities to Equity CRVO|ATHE: Short-Term Debt to Capital|Current Liabilities to Capital Clene (CLNN)|Short-Term Debt to Equity Ratio PEPG|Short-Term Debt to Capital jupiterneurosciences.com|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|Short-Term Loans to Capital Ratio ANVS|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|ANEW Medical, Inc. - Short-Term Debt to Capital|NeuroSense Therapeutics (NRSN) - Short-Term Debt to Equity Ratio|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|MTVA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio NRXS|Short-Term Debt to Equity HSDT|Short-Term Debt to Equity Ratio PASG (Passage Bio, Inc.)|NEUP - Current Liabilities to Capital|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Indebtedness to Equity Athira Pharma Inc|ADXN - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ALZN (Alzamend Neuro, Inc.)|cyclerion.com (CYCN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Cortigent Medical CRGT|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|Short-Term Debt to Capital BrainStorm Cell Therapeutics Inc. (BCLI)|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|Ratio of Short-Term Indebtedness to Capital CHRO|ELYM - Short-Term Debt to Equity|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|MRNS (Marinus Pharma) - Short-Term Debt to Equity|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Equity Ratio SAGE (Sage Therapeutics)|SNPX - Current Liabilities to Capital|Short-Term Debt to Capital TRVN (Trevena, Inc)|Short-Term Debt to Capital Vigil Neuroscience Inc. VIGL|Anew Medical, Inc. - Short-Term Debt to Capital|Short-Term Indebtedness to Equity cerevel.com (CERE)